Immunomodulation in Congenital Immunodeficiencies: Targeting Innate and Adaptive Pathways

Congenital immunodeficiencies, also known as primary immunodeficiency disorders (PIDs), comprise a heterogeneous group of inherited conditions affecting both innate and adaptive immune pathways. These disorders result in increased susceptibility to infections, immune dysregulation, and heightened risk of autoimmunity and malignancies. Advances in immunomodulatory strategies have transformed the management of these conditions, providing targeted therapeutic approaches to enhance immune function. This review explores key immunomodulatory mechanisms, including cytokine modulation, gene therapy, and cellular therapies, that are being developed to correct immune deficiencies. Emerging therapies such as CRISPR-based gene editing, monoclonal antibodies, and microbiome-based interventions hold great potential for improving patient outcomes. Understanding the interplay between innate and adaptive immunity in congenital immunodeficiencies is crucial for optimizing treatment strategies and developing novel interventions. Future research should focus on refining these approaches to achieve durable immune restoration and minimize adverse effects. Keywords: Congenital immunodeficiencies, primary immunodeficiency, immunomodulation, gene therapy, cytokine therapy